Inference of Tamoxifen's Effects on Prevention of Breast Cancer from a Randomized Controlled Trial.
The largest randomized, double-blind, placebo-controlled chemoprevention trial, the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial (NSABP-BCPT), evaluated the efficacy of tamoxifen in the prevention of breast cancer among women at high risk of developing the disease. The trial has reported a reduction of breast cancer incidence for the tamoxifen group. However, the effect of tamoxifen on the time to diagnosis of the disease over the six-year follow-up of the trial has not been fully explored in literature. We propose a flexible semiparametric model to assess the effects of tamoxifen on the incidence of breast cancer as well as time to the diagnosis of the disease, separately, in the framework of a cure-rate model. We used an estimating equation approach to estimating the unknown parameters, and assessed the semiparametric model assumption with a test based on the area between two survival curves. On the NSABP-BCPT data, we found that the treatment of tamoxifen has a substantial effect in the reduction of invasive breast cancer events in estrogen receptor (ER)-positive tumors, but has no effect on ER-negative tumors. Among women who were diagnosed to have ER-positive breast cancer during the study follow-up, there was little difference in terms of time to diagnosis between the two arms. However, tamoxifen may advance the time to breast cancer diagnosis for ER-negative breast cancer, while the incidence of ER-negative tumors is similar in the two treatment arms.
Shen
Yu
Y
Department of Biostatistics, M. D. Anderson Cancer Center, The University of Texas, Houston, TX 77030, .
Qin
Jing
J
Costantino
Joseph P
JP